New board members to provide expertise and guidance to help set strategic direction for Huma.AI into the future – appointments come during key phase of growth and expansion
PALO ALTO, Calif.–(BUSINESS WIRE)–Huma.AI, a leading healthcare AI company that provides transformative, human-centric machine learning technology solutions to help drive life science innovation, today announced the appointment of Karen Drexler to its board of directors and Jean-Olivier ‘J-O’ Racine to its strategic advisory board. Together, these esteemed individuals bring more than 40 years of healthcare and life science experience, digital health expertise, and entrepreneurial insights that will help guide Huma.AI’s continued growth serving its partners in the pharmaceutical, medical device, and in vitro diagnostics (IVD) sectors.
This expansion follows a recent round of funding in which the company secured $9.5 million in capital, and the addition of a post-market surveillance (PMS) capacity to its unique AI-based healthcare data knowledge platform. The new appointments double the number of Huma.AI’s advisors and are foundational to the company’s strategic plan to expand its team, technology, and products to meet the needs of its growing customer base.
“We’re thrilled to add these groundbreaking leaders to our two boards,” said Lana Feng, Ph.D., CEO and co-founder of Huma.AI. “They are value-creating changemakers in this era of rapid convergence of health and technology. The breadth and depth of their expertise and track records make them uniquely suited to help guide Huma.AI as we continue on a path of strategic growth and expansion.”
Karen Drexler, CEO of Sandstone DX, brings more than 20 years of experience co-founding and building medical device companies, mainly in the diagnostics space. Currently, Drexler serves as the CEO and board member of Sandstone DX, a company that is utilizing portable centrifugal technology to allow for plasma and serum collection at-home and the point of care. Drexler also serves as an independent director for ResMed, a market-leading company in the disordered breathing and digital health arenas. With extensive operational and entrepreneurial expertise, Drexler founded and ran Amira Medical until its sale to Roche Diabetes Care in 2001. An inventor on 11 issued patents, Drexler was named Female Entrepreneur of the Year by the Stevie Awards in 2013, and Entrepreneurial Woman of the Year by Silicon Valley Women’s Fund in 2002. In keeping with her passion for women’s health and leadership, she is active in Astia and Springboard, nonprofit organizations that support female entrepreneurs.
J-O Racine, Chief Technology Officer at Outset Medical, brings more than 20 years of experience in Enterprise IT. Currently, he oversees the strategic advancement of Outset Medical’s product technology, amplifying the company’s data-driven innovation engine to further elevate the patient care experience with dialysis and drive operating efficiencies for providers. Prior to joining Outset, Racine worked as the head of engineering and science for Amazon Web Services (AWS) Health AI where he managed Amazon Comprehend Medical, Amazon HealthLake and a variety of health services in development.
Drexler and Racine will join existing board members, Bassil Akra, Ph.D., CEO, Akra Team GMBH, and Yusung Chang, Ph.D., Co-Founder, Huma.AI.
Co-founded by Lana Feng Ph.D. and Greg Kostello, Huma.AI is a leading healthcare AI company offering a no-code/low-code knowledge automation platform that turns life science domain experts into their own data scientists. The name Huma means human plus machine—where humans always come first. Its transformative, human-centric AI platform has garnered tremendous industry recognition, and Huma.AI currently works with 10 large pharmaceutical, medical device, and IVD companies across the globe. Learn more at https://huma.ai.
Catalytic Agency on behalf of Huma.AI